Breaking News: U.S. FDA Approves Ruxolitinib Cream 1.5% (Opzelura, Incyte) for Kids Age 2 and up With AD
The FDA has approved ruxolitinib cream 1.5% (Opzelura Incyte) for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis (AD) in non-immunocompromised children two years of age and older whose disease is not well-controlled with topical prescription therapies, or when those therapies are not recommended.